Provided by Tiger Trade Technology Pte. Ltd.

MiNK Therapeutics, Inc.

12.44
-0.2900-2.28%
Post-market: 12.620.1800+1.45%19:33 EDT
Volume:48.87K
Turnover:610.23K
Market Cap:63.48M
PE:-5.19
High:12.72
Open:12.72
Low:12.10
Close:12.73
52wk High:16.93
52wk Low:8.48
Shares:5.10M
Float Shares:2.07M
Volume Ratio:1.81
T/O Rate:2.36%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.3970
EPS(LYR):-2.9257
ROE:-1238.98%
ROA:-123.84%
PB:-4.53
PE(LYR):-4.25

Loading ...

Press Release: MiNK Therapeutics Reports First Quarter 2026 Financial Results and Advances iNKT Cell Therapy Platform Into Randomized Clinical Validation

Dow Jones
·
May 15

MiNK Therapeutics initiates agenT-797 clinical trial

TIPRANKS
·
May 15

Mink Therapeutics and First Lviv Territorial Medical Union Initiate Randomized Phase 2 Trial of Agent-797 in Acute Lung Injury and Critical Illness

THOMSON REUTERS
·
May 14

Mink Therapeutics Inc: Preliminary Data Expected in Second Half of 2026

THOMSON REUTERS
·
May 14

MiNK Therapeutics and First Lviv Territorial Medical Union Initiate Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness

GlobeNewswire
·
May 14

Mink Therapeutics Inc expected to post a loss of 77 cents a share - Earnings Preview

Reuters
·
May 13

Mink Therapeutics data show agenT-797 iNKT cells drive context-dependent immune responses

Reuters
·
May 12

MiNK Therapeutics Presents Clinical Evidence That a Single, Off-the-Shelf, iNKT Cell Product Drives Context-Dependent Immune Responses at ASGCT 2026

GlobeNewswire
·
May 12

Mink Therapeutics Inc expected to post a loss of 77 cents a share - Earnings Preview

Reuters
·
May 11

Mink Therapeutics to report Q1 results, host conference call and webcast May 15

Reuters
·
May 09

Mink Therapeutics to Report First Quarter 2026 Financial Results and Highlight Platform Progress Across Inkt Cell Therapy Programs

THOMSON REUTERS
·
May 09

MiNK Therapeutics to Report First Quarter 2026 Financial Results and Highlight Platform Progress Across iNKT Cell Therapy Programs

GlobeNewswire
·
May 09

Mink Therapeutics announces annual shareholder meeting webcast

Reuters
·
May 01

Buy Rating on MiNK Therapeutics Driven by Promising Phase 2 Survival Benefit and Immune Activation in PD-1–Refractory Gastric Cancer

TIPRANKS
·
Apr 23

MiNK Therapeutics management to meet virtually with B. Riley

TIPRANKS
·
Apr 21

MiNK says Phase II trial posts 77% disease control in PD-1 refractory gastroesophageal cancer

Reuters
·
Apr 18

Mink Therapeutics Inc - Induction Strategy Improves Pfs and Survival Rates at 12 and 18 Months

THOMSON REUTERS
·
Apr 18

Mink Therapeutics Inc - Study Does Not Meet Primary Endpoint of Objective Response Rate

THOMSON REUTERS
·
Apr 18

Mink Therapeutics Reports Phase Ii Data on Immune Reprogramming and Durable Survival in Pd-1 Refractory Gastroesophageal Cancer

THOMSON REUTERS
·
Apr 18

Mink Therapeutics files Form 3 for Principal Financial Officer Melissa Orilall

Reuters
·
Apr 10